如何管理伴循环肿瘤细胞的新诊断多发性骨髓瘤
本文围绕新诊断多发性骨髓瘤(MM)伴循环肿瘤细胞(CTC)的诊疗挑战展开,指出流式细胞术检测2% CTC可识别预后与原发性浆细胞白血病(pPCL)相当的超高危MM亚组,CTC高于0.01%-0.07%是预后不良的独立预测因素,并讨论了将CTC检测纳入分期系统的方向。
要点
- 所有新诊断MM患者应通过形态学或流式细胞术评估外周血循环浆细胞,以及时鉴别MM与pPCL。
- 流式细胞术检测2% CTC可识别预后与pPCL相当的超高危MM亚组,这些患者可能受益于强化一线治疗或特定临床试验。
- CTC高于0.01%-0.07%是新诊断MM预后不良的独立预测因素,下一步是将CTC检测纳入现有分期系统。
核心结论
- 流式细胞术检测2% CTC可识别预后与pPCL相当的超高危MM亚组,这些患者可能受益于更强化的一线治疗或参加针对超高危MM和pPCL设计的特定临床试验。
- CTC高于0.01%-0.07%是新诊断MM预后不良的独立预测因素。
- 需要纳入不适合移植患者或结合新型免疫疗法的额外研究来确定明确的预后CTC截断值,下一步是将CTC检测纳入现有分期系统。
研究设计与样本
- 本文为Oncology Grand Rounds系列综述,通过病例展示、诊断与管理挑战描述、相关文献回顾及作者建议的管理方法总结,将原始报告置于临床背景中。
主要发现
- pPCL目前定义为循环浆细胞≥5%,但该截断值受到来自三个大型新诊断MM患者队列的新数据挑战,这些数据显示流式细胞术检测2% CTC可识别预后与pPCL相当的超高危MM亚组。
- CTC高于0.01%-0.07%的阈值(远低于定义pPCL的阈值)似乎是新诊断MM临床结局不良的独立预测因素。
- 与MM已取得的生存改善相比,pPCL的生存改善随时间推移更为有限。
关键数值与推荐
- pPCL目前定义为循环浆细胞≥5%。
- 流式细胞术检测2% CTC可识别预后与pPCL相当的超高危MM亚组。
- CTC高于0.01%-0.07%是新诊断MM预后不良的独立预测因素。
临床怎么用
- 所有新诊断MM患者应通过形态学评估或流式细胞术分析外周血循环浆细胞,作为诊断检查的必要组成部分,以及时鉴别MM与pPCL。
- CTC定量除鉴别MM与pPCL外,还可用于MM的风险分层。
- 流式细胞术检测2% CTC识别的超高危MM患者可能受益于更强化的一线治疗或参加针对超高危MM和pPCL设计的特定临床试验。
局限性
- 需要纳入不适合移植患者或结合新型免疫疗法的额外研究来确定明确的预后CTC截断值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.Careful evaluation of peripheral blood for the presence of circulating plasma cells by morphologic assessment or by flow cytometric analysis is an essential component of the diagnostic workup in all patients with newly diagnosed multiple myeloma (MM) to timely differentiate between MM and primary plasma cell leukemia (pPCL), which is the most aggressive plasma cell dyscrasia. The improvement in survival over time is more modest in pPCL, compared with what has been achieved in MM. pPCL is currently defined by the presence of ≥ 5% circulating plasma cells. However, this cutoff is now challenged by new data, from three large cohorts of patients with newly diagnosed MM, showing that a threshold of 2% circulating tumor cells (CTCs) by flow cytometry can be used to identify a subset of patients with ultra-high-risk MM with comparable prognosis as patients with pPCL. These patients may benefit from more intensified first-line therapies, or from enrollment into specific clinical trials, designed for ultra-high-risk MM and pPCL. Apart from differentiating MM from pPCL, the quantification of CTCs is also useful for risk stratification in MM. The detection of CTCs above a threshold of 0.01%-0.07% (much lower than the threshold to define pPCL) appears to be an independent predictor of poor clinical outcomes in newly diagnosed MM. Additional studies, including transplant-ineligible patients or with incorporation of novel immunotherapies, are needed to identify a definitive prognostic CTC cutoff. The next step will be the incorporation of CTC detection into existing staging systems to improve risk stratification and treatment personalization.
引用
- van de Donk NWCJ. How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells. J Clin Oncol. 2022. PMID: 36450104. doi:10.1200/JCO.22.02114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。